DGX Quest Diagnostics
- 155.120
- -0.360-0.23%
- 155.120
- 0.0000.00%
Quest Diagnostics News
Baird Adjusts Price Target on Quest Diagnostics to $155 From $154, Maintains Neutral
Evercore Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Quest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium Valuation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Quest Diagnostics Analyst Ratings
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $154
Barclays Remains a Hold on Quest Diagnostics (DGX)
Barclays Raises Quest Diagnostics' Price Target to $154 From $144, Maintains Equalweight Rating
JPMorgan Adjusts Price Target on Quest Diagnostics to $173 From $155, Maintains Neutral Rating
Quest Diagnostics: Strong Performance and Growth Trajectory Justify Buy Rating
Piper Sandler Adjusts Price Target on Quest Diagnostics to $150 From $145, Maintains Neutral Rating
Quest Diagnostics Analyst Ratings
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $150
Mizuho Securities Raises Quest Diagnostics' Price Target to $160 From $155
Maintaining Neutral Hold on Quest Diagnostics Amid Modest Growth and Pending Strategic Insights
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $154 From $153
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $150
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $144 to $154
Analysis
Price Target
No Data
No Data
